Bronchoalveolar Lavage Fluid Proteome in Bronchiolitis Obliterans Syndrome: Possible Role for Surfactant Protein A in Disease Onset

Journal of Heart and Lung Transplantation

Volumn 26, Issue 11, 2007, Pages 1135-1143

  Meloni, Federica ^a   Salvini, Roberta ^a   Bardoni, Anna Maria ^a   Passadore, Ileana ^a   Solari, Nadia ^a   Vitulo, Patrizio ^b   Oggionni, Tiberio ^a   Viganò, Mario ^a   Pozzi, Ernesto ^a   Fietta, Anna Maria ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; PEROXIREDOXIN; STEROID; SURFACTANT PROTEIN A;

ADULT; AGED; ARTICLE; BRONCHIOLITIS OBLITERANS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; LUNG LAVAGE; LUNG TRANSPLANTATION; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADULT; AGED; BIOLOGICAL MARKERS; BRONCHIOLITIS OBLITERANS; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; FEMALE; GRAFT REJECTION; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PEROXIREDOXINS; PREDICTIVE VALUE OF TESTS; PROTEOME; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; RISK FACTORS;

EID: 36048960756     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.08.009     Document Type: Article

References (52)

1. Boehler A., and Estenne M. Obliterative bronchiolitis after lung transplantation. Curr Opin Pulm Med 6 (2000) 133-139
2. Estenne M., Maurer J.R., Boehler A., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21 (2002) 297-310
3. Moffatt S.D., Demers P., Robbins R.C., et al. Lung transplantation: a decade of experience. J Heart Lung Transplant 24 (2005) 145-151
4. Cooper J.D., Billingham M., Egan T., et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 12 (1993) 713-716
5. Garone S., and Ross D.J. Bronchiolitis obliterans syndrome. Curr Opin Organ Transplant 4 (1999) 254-263
6. Meloni F., Vitulo P., Cascina A., et al. Bronchoalveolar lavage cytokine profile in a cohort of lung transplant recipients: a predictive role of interleukin-12 with respect to onset of bronchiolitis obliterans syndrome. J Heart Lung Transplant 23 (2004) 1053-1060
7. Nord M., Schubert K., Cassel T.N., Andersson O., and Riise G.C. Decreased serum and bronchoalveolar lavage levels of Clara cell secretory protein (CC16) is associated with bronchiolitis obliterans syndrome and airway neutrophilia in lung transplant recipients. Transplantation 27 (2002) 1264-1269
8. Riise G.C., Andersson B.A., Kjellstrom C., et al. Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant. Eur Respir J 14 (1999) 1123-1130
9. Taghavi S., Krenn K., Jaksch P., Klepetko W., and Aharinejad S. Broncho-alveolar lavage matrix metalloproteases as a sensitive measure of bronchiolitis obliterans. Am J Transplant 5 (2005) 1548-1552
10. Belperio J.A., Keane M.P., Burdick M.D., et al. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 115 (2005) 1150-1162
11. Suga M., Maclean A.A., Keshavjee S., et al. RANTES plays an important role in the evolution of allograft transplant-induced fibrous airway obliteration. Am J Respir Crit Care Med 162 (2000) 1940-1948
12. Slebos D.J., Postma D.S., Koeter G.H., et al. Bronchoalveolar lavage fluid characteristics in acute and chronic lung transplant rejection. J Heart Lung Transplant 23 (2004) 532-540
13. Neuringer I.P., Chalermskulrat W., and Aris R. Obliterative bronchiolitis or chronic lung allograft rejection: a basic science review. J Heart Lung Transplant 24 (2005) 3-19
14. Nelsestuen G.L., Martinez M.B., Hertz M.I., Savik K., and Wendt C.H. Proteomic identification of human neutrophil alpha defensins in chronic lung allograft rejection. Proteomics 5 (2005) 1705-1713
15. Zhang Y., Wroblewski M., Hertz M.I., Wendt C.H., Cervenka T.M., and Nelsestuen G.L. Analysis of chronic lung transplant rejection by MALDI-TOF profiles of bronchoalveolar lavage fluid. Proteomics 6 (2006) 1001-1010
16. Wattiez R., Hermans C., Bernard A., Lesur O., and Falmagne P. Human bronchoalveolar lavage fluid: two-dimensional gel electrophoresis, amino acid microsequencing and identification of major proteins. Electrophoresis 20 (1999) 1634-1645
17. Wattiez R., Hermans C., Cruyt C., Bernard A., and Falmagne P. Human bronchoalveolar lavage fluid protein two-dimensional database: study of interstitial lung diseases. Electrophoresis 21 (2000) 2703-2712
18. Magi B., Bini L., Perari M.G., et al. Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study. Electrophoresis 23 (2002) 3434-3444
19. Sabounchi-Schutt F., Astrom J., Hellman U., Eklund A., and Grunewald J. Changes in bronchoalveolar lavage fluid proteins in sarcoidosis: a proteomics approach. Eur Respir J 21 (2003) 414-420
20. Wattiez R., and Falmagne P. Proteomics of bronchoalveolar lavage fluid. J Chromatogr B Anal Technol Biomed Life Sci 815 (2005) 169-178
21. Rottoli P., Magi B., Perari M.G., et al. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5 (2005) 1423-1430
22. Fietta A.M., Bardoni A.M., Salvini R., et al. Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis. Arthritis Res Ther 8 (2006) R160
23. Yousem S.A., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group (LRSG). J Heart Lung Transplant 15 (1996) 1-15
24. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group. Eur Respir J 2 (1989) 561-585
25. Wilkins M.R., Appel R.D., Van Eyk J.E., et al. Guidelines for the next 10 years of proteomics. Proteomics 6 (2006) 4-8
26. Meloni F., Alberti A., Bulgheroni A., et al. Surfactant apoprotein A modulates interleukin-8 and monocyte chemotactic peptide-1 production. Eur Respir J 19 (2002) 1128-1135
27. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
28. Dziegielewska K., Brown W.M., Deal A., Foster K.A., Fry E.J., and Saunders N.R. The expression of fetuin in the development and maturation of the hemopoietic and immune systems. Histochem Cell Biol 106 (1996) 319-330
29. O'Donnell L.C., Druhan L.J., and Avalos B.R. Molecular characterization and expression analysis of leucine-rich alpha2-glycoprotein, a novel marker of granulocytic differentiation. J Leukoc Biol 72 (2002) 478-485
30. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Mol Immunol 38 (2001) 189-197
31. Rhee S.G., Kang S.W., Jeong W., et al. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr Opin Cell Biol 17 (2005) 183-189
32. Kang S.W., Chae H.Z., Seo M.S., et al. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-α. J Biol Chem 273 (1998) 6297-6302
33. Park J.H., Kim Y.S., Lee H.L., et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 11 (2006) 269-275
34. Jin L., Shin B.K., Jung W.Y., et al. Proteomic analysis of pulmonary sclerosing hemangioma. Proteomics 6 (2006) 4877-4883
35. Han Y.H., Kwon J.H., Yu D.Y., and Moon E.Y. Inhibitory effect of peroxiredoxin II (Prx II) on Ras-ERK-NfkappaB pathway in mouse embryonic fibroblast (MEF) senescence. Free Radic Res 40 (2006) 1182-1189
36. Low F.M., Hampton M.B., Peskin A.V., and Winterbourn C.C. Peroxiredoxin 2 functions as a noncatalytic scavenger of low-level hydrogen peroxide in the erythrocyte. Blood 109 (2007) 2611-2617
37. Phalen T.J., Weirather K., Deming P.B., et al. Oxidation state governs structural transitions in peroxiredoxin II that correlate with cell cycle arrest and recovery. J Cell Biol 175 (2006) 779-789
38. Kinnula V.L., Lehtonen S., Kaarteenaho-Wiik R., et al. Cell specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis. Thorax 57 (2002) 157-164
39. Kishore U., Greenhough T.J., Waters P., et al. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol 43 (2006) 1293-1315
40. Wright J.R. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 5 (2005) 58-68
41. Sano H., and Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol 42 (2005) 279-287
42. Yang S., Milla C., Panoskaltsis-Mortari A., et al. Human surfactant protein a suppresses T cell-dependent inflammation and attenuates the manifestations of idiopathic pneumonia syndrome in mice. Am J Respir Cell Mol Biol 24 (2001) 527-536
43. Tagaram H.R., Wang G., Umstead T.M., et al. Characterization of a human surfactant protein A1 (SP-A1) gene-specific antibody; SP-A1 content variation among individuals of varying age and pulmonary health. Am J Physiol Lung Cell Mol Physiol 292 (2007) L1052-L1063
44. Heinrich S., Hartl D., and Griese M. Surfactant protein A-from genes to human lung diseases. Curr Med Chem 13 (2006) 3239-3252
45. Casals C., Varela A., Ruano M.L., et al. Increase of C-reactive protein and decrease of surfactant protein A in surfactant after lung transplantation. Am J Respir Crit Care Med 157 (1998) 43-49
46. Scott A.I., Sharples L.D., and Stewart S. Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies. Drugs 65 (2005) 761-771
47. Hussain S. Role of surfactant protein A in innate host defense and autoimmunity. Autoimmunity 37 (2004) 125-130
48. Brinker K.G., Garner H., and Wright J.R. Surfactant protein A modulates the differentiation of murine bone marrow-derived dendritic cells. Am J Physiol Lung Cell Mol Physiol 284 (2003) L232-L241
49. Rubio F., Cooley J., Accurso F.J., and Remold-O'Donnell E. Linkage of neutrophil serine proteases and decreased surfactant protein-A (SP-A) levels in inflammatory lung disease. Thorax 59 (2004) 318-323
50. Mariencheck W.I., Alcorn J.F., Palmer S.M., and Wright J.R. Pseudomonas aeruginosa elastase degrades surfactant proteins A and D. Am J Respir Cell Mol Biol 28 (2003) 528-537
51. D'Ovidio F., Mura M., Ridsdale R., et al. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am J Transplant 6 (2006) 1930-1938
52. Hoover R.R., and Floros J. SP-A 3′-UTR is involved in the glucocorticoid inhibition of human SP-A gene expression. Am J Physiol Lung Cell Mol Physiol 276 (1999) L917-L924